Skip to content

U-100 unit conversion

Retatrutide calculator

Convert mass and volume to U-100 units. No dose is selected.

These are example numbers so you can see the math. Try yours. Change them to match the vial in your hand.

8.3U-100 units · 0.083 mL

30 mcg per unit · 3000 mcg/mL

How the calculator works, sources and review dates

Retatrutide math uses the listed vial sizes on this card and the liquid you type. Concentration in mcg per mL is vial milligrams times 1000, divided by milliliters. A U-100 syringe has 100 marks per milliliter, so each unit is that concentration divided by 100. Example numbers so you can see the math: a 6 mg listing plus 2 mL of liquid. Change any number and the units change. Try the numbers. A research-market vial is not the same material used in a trial.

Editorial review 2026-10-09. source-curated; clinician review pending.

Units chart for listed Retatrutide sizes

U-100 math for listed Retatrutide sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.

Micrograms per U-100 unit (100 marks / mL)
Listed vial1 mL liquid2 mL liquid3 mL liquid
6 mg603020
10 mg1005033.3
12 mg1206040
30 mg300150100

What is Retatrutide?

Seller aliases include R-10, R-30, and several milligram labels. Those names are not proven matches for Lilly trial material. Oral, nasal, or “premium” research listings do not inherit trial results. The mechanism language here comes from the study program. It is not a wellness claim.

What the evidence says

For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.

Human trial

TRIUMPH-2: peer-reviewed Phase 3 results (September 2026)

Adults with obesity and type 2 diabetes; published online September 29, 2026.

Reported findings. TRIUMPH-2 randomized 1,152 adults with obesity and type 2 diabetes. At week 80, mean weight change in the treatment-regimen estimand was -11.9%, -16.8% and -18.8% across the experimental arms versus -5.1% with placebo; glycemic control also improved.

Nonresponse. Nonresponse frequency not established in this excerpt.

Harms. Gastrointestinal adverse events, hypotension and dysesthesia were more frequent with retatrutide. Discontinuation due to adverse events or death was 12% and 8% in two experimental arms, versus 4% in the other arm and 5% with placebo. Investigators considered all reported deaths unrelated to study intervention.

Limits. Sponsor-funded trial of controlled study material. Results do not establish approval or equivalence of commercial research preparations. Different statistical estimands yield different headline weight-loss percentages.

Preparation: Source preparation; commercial equivalence unverified. Route: subcutaneous

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Regulatory status, dated 2026-10-09

FDA product approval

not approved. FDA identifies this investigational substance as unapproved.

Compounding

restricted. FDA states this substance cannot be used in compounding under federal law.

Research

investigational. Human obesity trials; trial findings do not authorize unsupervised use.

Sport

unknown. Not individually verified; consult the current sport rules. Absence of a listing is not permission.

How long it lasts, how you store it, listed sizes

This entry doesn’t give a duration in hours. No verified formulation-specific human estimate in this source set; no guessed value is supplied.

The vendor file lists 6 mg, 10 mg, 12 mg, and 30 mg research sizes. Trial storage is not a home plan. Read the label on the vial you hold. Shelf the paper. An R-30 listing is a seller title, and the TRIUMPH-2 paper measured a defined study product over 80 weeks in 1,152 adults, so those two objects stay on separate shelves.

Risks and mix-ups already on the record

  • Safety is incomplete; absence of reports does not establish safety.
  • Phase 3 reports include hypotension and dysesthesia (altered sensation), alongside gastrointestinal adverse effects.
  • Unknown or incomplete for research formulations; this is not a clearance for use.
  • Unknown or incomplete; do not infer compatibility with medications or other substances.

People using PepBear often log: Dated weight, symptoms and clinician-directed metabolic records, alongside other medicines and activity. Record missing observations and changes in appetite, gastrointestinal symptoms and sensation; the app does not infer a treatment effect.

Sources

  1. Primary evidence or regulator source · checked 2026-10-09
  2. FDA unapproved GLP-1 safety statement · checked 2026-10-09
  3. TRIUMPH-2: peer-reviewed Phase 3 results (September 2026) · checked 2026-10-09
  4. ClinicalTrials.gov retatrutide records · checked 2026-10-09

Questions people ask

Is retatrutide approved in 2026?

As of Oct 9, 2026 the catalog records it as not approved. FDA says compounding is restricted under federal law.

Can a mix chart replace the trial amount?

Trial amounts belong to the cited protocol and study material. The chart only turns a labeled vial mass and a liquid volume into U-100 units for numbers you type.

How many units is a listed Retatrutide vial after you add water?

Units = (amount in mcg ÷ (vial mg × 1000 ÷ water mL)) × 100 on a U-100 syringe. Enter the three numbers. The chart shows the same math for each listed vial size and 1, 2 or 3 mL of liquid.

Why flag amounts under 5 units?

A U-100 barrel is easy to misread below about 5 marks. That is a measuring warning. The page does not tell you to take more.

Related cards

A licensed clinician must interpret the evidence for your situation. This entry provides education, not treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.